At a glance
| Product | Trulicity |
|---|---|
| Target | GLP-1 receptor |
| Route | Subcutaneous injection |
| Diabetes age scope | 10 years and older |
| Outcome trial | REWIND |
Overview
Trulicity contains dulaglutide, a long-acting GLP-1 receptor agonist designed for weekly subcutaneous use. Its U.S. indication includes glycemic control in adults and children aged ten and older with type 2 diabetes. A separate adult indication reduces major cardiovascular events in people with established cardiovascular disease or multiple risk factors. The latter is broader than requiring a prior cardiovascular event, reflecting the REWIND trial population. Weight changes may accompany treatment, but that observation should not be rewritten as an obesity indication or a reason to combine it with another GLP-1 medicine.
How it works
Dulaglutide activates GLP-1 receptors, increasing beta-cell cyclic AMP and glucose-dependent insulin release. It also reduces glucagon secretion and delays gastric emptying. Fusion-protein engineering prolongs its exposure. The glucose-dependent mechanism reduces, but does not abolish, hypoglycemia concerns; risk becomes more important when insulin or insulin secretagogues are also part of the treatment regimen.
Current label boundaries
The diabetes indication includes adults and children ten or older. Cardiovascular risk reduction applies to adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. It is not a type 1 diabetes treatment.
Supporting sources [1]
What REWIND contributes
REWIND showed fewer major cardiovascular events with dulaglutide than placebo in adults with type 2 diabetes, including many without a previous event. This supports the risk-factor-based label and should be distinguished from trials restricted to secondary prevention.
Supporting sources [2]
Major adverse effects and exclusions
Gastrointestinal symptoms are common. Pancreatitis, gallbladder disease, dehydration-related kidney injury and serious allergy are recognized concerns. A personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication related to the thyroid C-cell tumor warning.
Supporting sources [1]
Other clinical considerations
The label addresses diabetic retinopathy complications, severe gastroparesis and aspiration during anesthesia or deep sedation. Glucose monitoring becomes especially relevant with concurrent insulin or secretagogues, while dehydration can increase kidney risk.
Supporting sources [1]
Does weekly delivery mean identical GLP-1 effects?
No. Each medicine has its own molecule, exposure, approved populations and outcomes trials. Dulaglutide’s cardiovascular evidence should not be assigned to every GLP-1 product, and another product’s weight-management approval does not extend to Trulicity.
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: GLP-1 receptor agonist fusion protein.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Trulicity current prescribing information ↗Regulatory source · Checked 2026-10-27
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. ↗Original research · Checked 2026-10-27